Afrasiabi A, Parnell GP, Fewings N, Schibeci SD, Basuki MA, Chandramohan R, Zhou Y, Taylor B, Brown DA, Swaminathan S, McKay FC, Stewart GJ, Booth DR (2019). Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility. Genome Med 11: 26.
Alfredsson L, Olsson T (2019). Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harb Perspect Med 9.
Almohmeed YH, Avenell A, Aucott L, Vickers MA (2013). Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One 8: e61110.
Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B (2004). Epstein-Barr virus in pediatric multiple sclerosis. JAMA 291: 1875-9.
Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernan MA, Olek MJ, Hankinson SE, Hunter DJ (2001). Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286: 3083-8.
Beseler C, Vollmer T, Graner M, Yu X (2017). The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution. PLoS One 12: e0186842.
Bray PF, Luka J, Bray PF, Culp KW, Schlight JP (1992). Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 42: 1798-804.
Burnard S, Lechner-Scott J, Scott RJ (2017). EBV and MS: Major cause, minor contribution or red-herring? Mult Scler Relat Disord 16: 24-30.
Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Bussow K, Sommer N, Hemmer B (2005). Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115: 1352-60.
Chen F, Zou JZ, di Renzo L, Winberg G, Hu LF, Klein E, Klein G, Ernberg I (1995). A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69: 3752-8.
Cohen JI (2000). Epstein-Barr virus infection. N Engl J Med 343: 481-92.
Comabella M, Kakalacheva K, Rio J, Munz C, Montalban X, Lunemann JD (2012). EBV-specific immune responses in patients with multiple sclerosis responding to IFNbeta therapy. Mult Scler 18: 605-9.
Comabella M, Montalban X, Horga A, Messmer B, Kakalacheva K, Strowig T, Caballero E, Munz C, Lunemann J (2010). Antiviral immune response in patients with multiple sclerosis and healthy siblings. Mult Scler 16: 355-8.
Compston A, Coles A (2008). Multiple sclerosis. Lancet 372: 1502-17.
DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A (2006). Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63: 839-44.
Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, Khaleeli Z, Schmierer K, Miller DH, Giovannoni G (2009). Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73: 32-8.
Ferrer M, Harrison SC (1999). Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol 73: 5795-802.
Graner M, Pointon T, Manton S, Green M, Dennison K, Davis M, Braiotta G, Craft J, Edwards T, Polonsky B, Fringuello A, Vollmer T, Yu X (2020). Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. PLoS One 15: e0228883.
Haahr S, Hollsberg P (2006). Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol 16: 297-310.
Hecker M, Fitzner B, Wendt M, Lorenz P, Flechtner K, Steinbeck F, Schroder I, Thiesen HJ, Zettl UK (2016). High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Mol Cell Proteomics 15: 1360-80.
Heiskanen T, Lundkvist A, Soliymani R, Koivunen E, Vaheri A, Lankinen H (1999). Phage-displayed peptides mimicking the discontinuous neutralization sites of puumala Hantavirus envelope glycoproteins. Virology 262: 321-32.
Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004). Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 78: 5194-204.
Honarmand H, Ahmadi Jalali Moghadam M, Hatamian H, Roudbary A (2015). Possible Relations Between Epstein-Barr Virus Past Infection and Classic Multiple Sclerosis in Guilan, Iran. Jundishapur J Microbiol 8: e15985.
Hutchinson M (2013). Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: commentary. Mult Scler 19: 1694-5.
Jespersen MC, Peters B, Nielsen M, Marcatili P (2017). BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res 45: W24-W29.
Kolaskar AS, Tongaonkar PC (1990). A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 276: 172-4.
Lamiable A, Thevenet P, Rey J, Vavrusa M, Derreumaux P, Tuffery P (2016). PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res 44: W449-54.
Laurence M, Benito-Leon J (2017). Epstein-Barr virus and multiple sclerosis: Updating Pender's hypothesis. Mult Scler Relat Disord 16: 8-14.
Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A (2005). Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293: 2496-500.
Lucas RM, Hughes AM, Lay ML, Ponsonby AL, Dwyer DE, Taylor BV, Pender MP (2011). Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 82: 1142-8.
Lunemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Munz C, Martin R (2006). Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129: 1493-506.
Lunemann JD, Huppke P, Roberts S, Bruck W, Gartner J, Munz C (2008a). Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 71: 1033-5.
Lunemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Munz C (2008b). EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205: 1763-73.
Lunemann JD, Kamradt T, Martin R, Munz C (2007). Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol 81: 6777-84.
Lunemann JD, Tintore M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Munz C, Montalban X, Comabella M (2010). Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 67: 159-69.
Mameli G, Cossu D, Cocco E, Masala S, Frau J, Marrosu MG, Sechi LA (2014). Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. J Neuroimmunol 270: 51-5.
Mameli G, Madeddu G, Cossu D, Galleri G, Manetti R, Babudieri S, Mura MS, Sechi LA (2016). Immune response induced by Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides in current and past infectious mononucleosis: a risk for multiple sclerosis? Eur J Neurol 23: 140-7.
Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D'Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D'Alfonso S, Pesole G, Salvetti M, Ristori G (2015). Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology 84: 1362-8.
Nielsen TR, Pedersen M, Rostgaard K, Frisch M, Hjalgrim H (2007). Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler 13: 420-3.
Nociti V, Frisullo G, Marti A, Luigetti M, Iorio R, Patanella AK, Bianco A, Tonali PA, Grillo RL, Sabatelli M, Batocchi AP (2010). Epstein-Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis. J Neuroimmunol 225: 149-52.
Owens GP, Bennett JL (2012). Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis. Mult Scler 18: 1204-8.
Owens GP, Burgoon MP, Devlin ME, Gilden DH (1997). Extraction and purification of active IgG from SSPE and MS brain. J Virol Methods 68: 119-25.
Owens GP, Shearer AJ, Yu X, Ritchie AM, Keays KM, Bennett JL, Gilden DH, Burgoon MP (2006). Screening random peptide libraries with subacute sclerosing panencephalitis brain-derived recombinant antibodies identifies multiple epitopes in the C-terminal region of the measles virus nucleocapsid protein. J Virol 80: 12121-30.
Pakpoor J, Giovannoni G, Ramagopalan SV (2013). Epstein-Barr virus and multiple sclerosis: association or causation? Expert Rev Neurother 13: 287-97.
Pakpoor J, Ramagopalan SV (2013). Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: yes. Mult Scler 19: 1690-1.
Pender MP, Csurhes PA, Burrows JM, Burrows SR (2017). Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin Transl Immunology 6: e126.
Pender MP, Csurhes PA, Lenarczyk A, Pfluger CM, Burrows SR (2009). Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 80: 498-505.
Ramasamy R, Mohammed F, Meier UC (2020). HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein-Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis. Immunol Lett 217: 15-24.
Rand KH, Houck H, Denslow ND, Heilman KM (1998). Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. J Neurol Neurosurg Psychiatry 65: 48-55.
Rand KH, Houck H, Denslow ND, Heilman KM (2000). Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 173: 32-9.
Ricigliano VA, Handel AE, Sandve GK, Annibali V, Ristori G, Mechelli R, Cader MZ, Salvetti M (2015). EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy. PLoS One 10: e0119605.
Rowe M, Fitzsimmons L, Bell AI (2014). Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer 33: 609-19.
Rudolf MP, Vogel M, Kricek F, Ruf C, Zurcher AW, Reuschel R, Auer M, Miescher S, Stadler BM (1998). Epitope-specific antibody response to IgE by mimotope immunization. J Immunol 160: 3315-21.
Saha S, Raghava GP (2006). Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 65: 40-8.
Salzer J, Myhr KM (2013). Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: no. Mult Scler 19: 1692-3.
Shannon-Lowe C, Rickinson A (2019). The Global Landscape of EBV-Associated Tumors. Front Oncol 9: 713.
Sundqvist E, Sundstrom P, Linden M, Hedstrom AK, Aloisi F, Hillert J, Kockum I, Alfredsson L, Olsson T (2012). Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 13: 14-20.
Sundstrom P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nystrom L, Dillner J, Forsgren L (2004). An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62: 2277-82.
Tengvall K, Huang J, Hellstrom C, Kammer P, Bistrom M, Ayoglu B, Lima Bomfim I, Stridh P, Butt J, Brenner N, Michel A, Lundberg K, Padyukov L, Lundberg IE, Svenungsson E, Ernberg I, Olafsson S, Dilthey AT, Hillert J, Alfredsson L, Sundstrom P, Nilsson P, Waterboer T, Olsson T, Kockum I (2019). Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci U S A 116: 16955-16960.
Thacker EL, Mirzaei F, Ascherio A (2006). Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 59: 499-503.
Tierney R, Nagra J, Hutchings I, Shannon-Lowe C, Altmann M, Hammerschmidt W, Rickinson A, Bell A (2007). Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J Virol 81: 10092-100.
Tierney RJ, Steven N, Young LS, Rickinson AB (1994). Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68: 7374-85.
Turner JS, Marthi M, Benet ZL, Grigorova I (2017). Transiently antigen-primed B cells return to naive-like state in absence of T-cell help. Nat Commun 8: 15072.
van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM (2016). Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler 22: 279-91.
van Noort JM, Baker D, Amor S (2012). Mechanisms in the development of multiple sclerosis lesions: reconciling autoimmune and neurodegenerative factors. CNS Neurol Disord Drug Targets 11: 556-69.
van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM (1999). EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 162: 129-35.
Warner HB, Carp RI (1981). Multiple sclerosis and Epstein-Barr virus. Lancet 2: 1290.
Wu H, Kapoor P, Frappier L (2002). Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol 76: 2480-90.
Yao B, Zhang L, Liang S, Zhang C (2012). SVMTriP: a method to predict antigenic epitopes using support vector machine to integrate tri-peptide similarity and propensity. PLoS One 7: e45152.
Yu X, Burgoon M, Green M, Barmina O, Dennison K, Pointon T, Davis M, Gilden D (2011a). Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time. J Neuroimmunol 240-241: 129-36.
Yu X, Burgoon MP, Shearer AJ, Gilden DH (2007). Characterization of phage peptide interaction with antibody using phage mediated immuno-PCR. J Immunol Methods 326: 33-40.
Yu X, Gilden D, Schambers L, Barmina O, Burgoon M, Bennett J, Owens G (2011b). Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF. J Neuroimmunol 233: 192-203.
Yu X, Gilden DH, Ritchie AM, Burgoon MP, Keays KM, Owens GP (2006a). Specificity of recombinant antibodies generated from multiple sclerosis cerebrospinal fluid probed with a random peptide library. J Neuroimmunol 172: 121-31.
Yu X, Owens GP, Gilden DH (2006b). Rapid and efficient identification of epitopes/mimotopes from random peptide libraries. J Immunol Methods 316: 67-74.
Zhang M, Davidson A (1999). A rheumatoid factor specific mimotope identified by a peptide display library. Autoimmunity 30: 131-42.
Zhu Z, Li R, Stricker R, Reiser G (2015). Extracellular alpha-crystallin protects astrocytes from cell death through activation of MAPK, PI3K/Akt signaling pathway and blockade of ROS release from mitochondria. Brain Res 1620: 17-28.